drugset / Trial / NCT00881608

Study to Evaluate Menses Induction in Women Administered Proellex

NCT00881608

Phase 1 Terminated 11 enrolled Repros Therapeutics Inc.
Non-randomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to determine the oral dose level at which the investigative drug, Proellex, is able induce menstruation.

Timeline

Start
2009-02
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Telapristone Acetate Other / unclassified 3 mg Oral
Subject Telapristone Acetate Other / unclassified 6 mg Oral
Subject Telapristone Acetate Other / unclassified 12 mg Oral
Subject Telapristone Acetate Other / unclassified 25 mg Oral

Indications